We report the synthesis and biological evaluation of a new series of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives (compounds 1-4) bearing appropriate substitutions in positions 7 and/or 8. The objective of this investigation was to study the effects of these substitutions on the cytotoxic activity of four new compounds against established human cancer cell lines (i.e. HT29 and HCT-8, colon carcinoma, MCF7, breast carcinoma, and A549, lung carcinoma cells). The inhibitory effects of compounds 1-4 on cell growth were assessed by the sulforhodamine B assay. Also, the effects of these compounds on cell cycle distribution of human colon carcinoma cells (HCT-8) were analyzed by flow cytometry. 3-Nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives displayed IC(50) values in the micromolar range on the growth of the four cell lines tested. Cell cycle perturbations induced on HCT-8 cells by study compounds at the IC(50) values consisted prevalently of a slight accumulation of cells in G(0)/G(1) phase and a slight decrease in G(2)/M phase. However, compound 3 induced a marked accumulation of cells into S phase with concomitant decrease in G(0)/G(1) and G(2)/M phases. Cytotoxicity data, compared to those obtained with 3-cyano-8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide (compound 5, NSC 683334) and other compounds previously synthesized in our laboratory, demonstrated a similar or even improved cytotoxic potency. Cell cycle perturbations caused by these compounds support the hypothesis that they may act by a direct or an indirect inhibition of DNA synthesis.
Cytotoxic activity of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives: a new series of anti-proliferative agents / M. CORONNELLO; G. CICIANI; E. MINI; G. GUERRINI; B. CACIAGLI; S. SELLERI; A. COSTANZO; T. MAZZEI. - In: ANTI-CANCER DRUGS. - ISSN 0959-4973. - ELETTRONICO. - 16:(2005), pp. 645-651. [10.1097/00001813-200507000-00009]
Cytotoxic activity of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives: a new series of anti-proliferative agents.
CORONNELLO, MARCELLA MARIA;CICIANI, GIOVANNA;MINI, ENRICO;GUERRINI, GABRIELLA;SELLERI, SILVIA;COSTANZO, ANNARELLA;MAZZEI, TERESITA
2005
Abstract
We report the synthesis and biological evaluation of a new series of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives (compounds 1-4) bearing appropriate substitutions in positions 7 and/or 8. The objective of this investigation was to study the effects of these substitutions on the cytotoxic activity of four new compounds against established human cancer cell lines (i.e. HT29 and HCT-8, colon carcinoma, MCF7, breast carcinoma, and A549, lung carcinoma cells). The inhibitory effects of compounds 1-4 on cell growth were assessed by the sulforhodamine B assay. Also, the effects of these compounds on cell cycle distribution of human colon carcinoma cells (HCT-8) were analyzed by flow cytometry. 3-Nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives displayed IC(50) values in the micromolar range on the growth of the four cell lines tested. Cell cycle perturbations induced on HCT-8 cells by study compounds at the IC(50) values consisted prevalently of a slight accumulation of cells in G(0)/G(1) phase and a slight decrease in G(2)/M phase. However, compound 3 induced a marked accumulation of cells into S phase with concomitant decrease in G(0)/G(1) and G(2)/M phases. Cytotoxicity data, compared to those obtained with 3-cyano-8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide (compound 5, NSC 683334) and other compounds previously synthesized in our laboratory, demonstrated a similar or even improved cytotoxic potency. Cell cycle perturbations caused by these compounds support the hypothesis that they may act by a direct or an indirect inhibition of DNA synthesis.File | Dimensione | Formato | |
---|---|---|---|
Anticancer drugs 2005.pdf
accesso aperto
Tipologia:
Versione finale referata (Postprint, Accepted manuscript)
Licenza:
Open Access
Dimensione
136.62 kB
Formato
Adobe PDF
|
136.62 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.